Previous close | 17.00 |
Open | 17.00 |
Bid | 0.00 |
Ask | 0.00 |
Strike | 60.00 |
Expiry date | 2024-10-18 |
Day's range | 17.00 - 17.00 |
Contract range | N/A |
Volume | |
Open interest | N/A |
We can readily understand why investors are attracted to unprofitable companies. Indeed, Twist Bioscience ( NASDAQ:TWST...
Here is how DaVita HealthCare (DVA) and Twist Bioscience (TWST) have performed compared to their sector so far this year.
SOUTH SAN FRANCISCO, Calif., June 06, 2024--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the publication of a study detailing the discovery of TB206-001, a first-in-class antibody targeting adenosine A2A receptor (A2AR), a promising molecular target that could enhance cancer immunotherapy. The study titled, "Discovery of a potent, selective, and tumor-suppressing